Evidence map›Paper›PMID 35955902›Full record

ReviewInternational journal of molecular sciences2022

Multitargeting the Action of 5-HT

Kinga Czarnota-Łydka, Katarzyna Kucwaj-Brysz, Patryk Pyka, Wawrzyniec Haberek, Sabina Podlewska, Jadwiga Handzlik

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Kinga Czarnota-ŁydkaDepartment of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.
Katarzyna Kucwaj-BryszDepartment of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0003-4408-9804
Patryk PykaDepartment of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.
Wawrzyniec HaberekDepartment of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.
Sabina PodlewskaMaj Institute of Pharmacology, Polish Academy of Sciences, Department of Medicinal Chemistry, Smętna Street 12, 31-343 Krakow, Poland.ORCID 0000-0002-2891-5603
Jadwiga HandzlikDepartment of Technology and Biotechnology of Drugs, Medical College, Jagiellonian University, Medyczna 9, 30-688 Krakow, Poland.ORCID 0000-0002-3674-3581
Jagiellonian University · PLMaj Institute of Pharmacology · PL

Funding

National Science Center UMO-2018/31/B/NZ7/02160
6 · The paper itself

Abstract

In view of the unsatisfactory treatment of cognitive disorders, in particular Alzheimer's disease (AD), the aim of this review was to perform a computer-aided analysis of the state of the art that will help in the search for innovative polypharmacology-based therapeutic approaches to fight against AD. Apart from 20-year unrenewed cholinesterase- or NMDA-based AD therapy, the hope of effectively treating Alzheimer's disease has been placed on serotonin 5-HT

Indexed as

Alzheimer DiseaseCognition DisordersAnimalsHumansLigandsReceptors, SerotoninSerotoninSerotonin AntagonistsLigandsReceptors, SerotoninSerotoninSerotonin Antagonists5-HT6 ligandsAlzheimer’s diseaseCDK5dementiaMARK4ROCKIROCKII

Identifiers

PMID35955902
PMCPMC9368844
OpenAlexW4290517333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.